Literature DB >> 33520872

Therapeutic potential of mesenchymal stem cells in treating both types of diabetes mellitus and associated diseases.

Vidul Goenka1, Tanhai Borkar1, Aska Desai1, Raunak Kumar Das2.   

Abstract

Diabetes mellitus is a common lifestyle disease which can be classified into type 1 diabetes mellitus and type 2 diabetes mellitus. While both result in hyperglycemia due to lack of insulin action and further associated chronic ailments, there is a marked distinction in the cause for each type due to which both require a different prophylaxis. As observed, type 1 diabetes is caused due to the autoimmune action of the body resulting in the destruction of pancreatic islet cells. On the other hand, type 2 diabetes is caused either due to insulin resistance of target cells or lack of insulin production as per physiological requirements. Attempts to cure the disease have been made by bringing drastic changes in the patients' lifestyle; parenteral administration of insulin; prescription of drugs such as biguanides, meglitinides, and amylin; pancreatic transplantation; and immunotherapy. While these attempts cause a certain degree of relief to the patient, none of these can cure diabetes mellitus. However, a new treatment strategy led by the discovery of mesenchymal stem cells and their unique immunomodulatory and multipotent properties has inspired therapies to treat diabetes by essentially reversing the conditions causing the disease. The current review aims to enumerate the role of various mesenchymal stem cells and the different approaches to treat both types of diabetes and its associated diseases as well. © Springer Nature Switzerland AG 2020.

Entities:  

Keywords:  Diabetes-associated diseases; Immunomodulation; Immunosuppression; Insulin resistance; Insulin-producing cells; Mesenchymal stem cells

Year:  2020        PMID: 33520872      PMCID: PMC7843693          DOI: 10.1007/s40200-020-00647-5

Source DB:  PubMed          Journal:  J Diabetes Metab Disord        ISSN: 2251-6581


  168 in total

1.  Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue.

Authors:  Susanne Kern; Hermann Eichler; Johannes Stoeve; Harald Klüter; Karen Bieback
Journal:  Stem Cells       Date:  2006-01-12       Impact factor: 6.277

2.  The role of IL-6 in inhibition of lymphocyte apoptosis by mesenchymal stem cells.

Authors:  Guangwu Xu; Yingyu Zhang; Liying Zhang; Guangwen Ren; Yufang Shi
Journal:  Biochem Biophys Res Commun       Date:  2007-07-20       Impact factor: 3.575

3.  The Pax4 gene is essential for differentiation of insulin-producing beta cells in the mammalian pancreas.

Authors:  B Sosa-Pineda; K Chowdhury; M Torres; G Oliver; P Gruss
Journal:  Nature       Date:  1997-03-27       Impact factor: 49.962

4.  Umbilical cord mesenchymal stem cell transfusion ameliorated hyperglycemia in patients with type 2 diabetes mellitus.

Authors:  Dexiao Kong; Xianghua Zhuang; Daoqing Wang; Huiting Qu; Yang Jiang; Xiaomei Li; Wenxiu Wu; Juan Xiao; Xiaoli Liu; Junli Liu; Ai Li; Juandong Wang; Aixia Dou; Yongjing Wang; Junhua Sun; Hong Lv; Guihua Zhang; Xuhua Zhang; Shihong Chen; Yihong Ni; Chengyun Zheng
Journal:  Clin Lab       Date:  2014       Impact factor: 1.138

5.  MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2.

Authors:  Grazia Maria Spaggiari; Heba Abdelrazik; Flavio Becchetti; Lorenzo Moretta
Journal:  Blood       Date:  2009-04-27       Impact factor: 22.113

6.  Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice.

Authors:  Fernando E Ezquer; Marcelo E Ezquer; Daniela B Parrau; Daniel Carpio; Alejandro J Yañez; Paulette A Conget
Journal:  Biol Blood Marrow Transplant       Date:  2008-04-14       Impact factor: 5.742

7.  Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide.

Authors:  Guangwen Ren; Liying Zhang; Xin Zhao; Guangwu Xu; Yingyu Zhang; Arthur I Roberts; Robert Chunhua Zhao; Yufang Shi
Journal:  Cell Stem Cell       Date:  2008-02-07       Impact factor: 24.633

8.  Diabetes treatment in 2025: can scientific advances keep pace with prevalence?

Authors:  Mansur Shomali
Journal:  Ther Adv Endocrinol Metab       Date:  2012-10       Impact factor: 3.565

9.  Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC.

Authors:  Ralf Hass; Cornelia Kasper; Stefanie Böhm; Roland Jacobs
Journal:  Cell Commun Signal       Date:  2011-05-14       Impact factor: 5.712

Review 10.  Recent Trends in Therapeutic Approaches for Diabetes Management: A Comprehensive Update.

Authors:  Pragya Tiwari
Journal:  J Diabetes Res       Date:  2015-07-27       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.